The Billion-Dollar Question: Why Are Health Premiums Skyrocketing?
The recent financial revelations from Excellus Blue Cross Blue Shield have left me scratching my head—and not just because of the eye-watering executive salaries. In 2025, the insurer collected a staggering $1 billion more in premiums than the previous year. Yet, despite this windfall, they ended up losing $108 million on their core insurance business. How is that even possible?
The Cost of Care: A Never-Ending Climb
One thing that immediately stands out is the relentless rise in healthcare costs. Excellus spent nearly all of that extra $1 billion on higher claims, driven by factors like increased utilization, pricier doctor bills, and an aging population demanding complex care. Personally, I think this highlights a deeper issue: the unsustainable trajectory of healthcare spending. What many people don’t realize is that innovations like Ozempic and Wegovy, while life-changing, come with price tags that are pushing the system to its limits.
From my perspective, this raises a broader question: Are we prioritizing innovation over affordability? Newer treatments are undoubtedly improving outcomes, but at what cost? If you take a step back and think about it, the system seems to be rewarding high-priced interventions without addressing the root causes of rising costs.
Executive Pay: A Detail That’s Hard to Ignore
Let’s talk about those executive salaries. Excellus’s top 10 executives saw a 6% increase in pay, totaling $15 million in 2025. CEO James Reed’s salary alone jumped from $4 million to $4.4 million. Now, I’m not here to begrudge anyone their earnings, but in a year where the company lost money on its core business, these figures feel tone-deaf.
What this really suggests is a disconnect between leadership compensation and the financial health of the organization. In my opinion, tying executive pay to profitability—or at least to cost-control metrics—would better align incentives with the company’s long-term sustainability.
The Non-Profit Paradox
Here’s where things get particularly fascinating: Excellus is a non-profit. Despite operating at a loss on insurance, they ended the year with a $150 million surplus, thanks to their investment portfolio. This surplus is then funneled into reserves to offset future losses.
What makes this particularly fascinating is the tension between their non-profit status and their financial strategies. On one hand, they’re not supposed to prioritize profits. On the other, they’re relying on investments to stay afloat. This raises a deeper question: Are non-profit insurers truly serving the public interest, or are they just another player in a broken system?
The Bigger Picture: A System in Crisis
If we zoom out, Excellus’s situation is a microcosm of the broader healthcare crisis. Premiums are rising, costs are spiraling, and insurers are struggling to keep up. What’s worse, the system seems designed to reward inefficiency. Administrative costs alone ate up $400 million of Excellus’s budget—and that’s after a slight decrease from the previous year.
A detail that I find especially interesting is how much of the premium dollar actually goes to care: just 92 cents. The rest is swallowed by administrative expenses, taxes, and other overheads. This isn’t just an Excellus problem—it’s a systemic issue.
Where Do We Go From Here?
Personally, I think the solution lies in radical transparency and accountability. If insurers were required to justify every dollar spent, we might see a shift toward more efficient models. Additionally, policymakers need to address the root causes of rising costs, from drug pricing to over-reliance on expensive treatments.
What this really suggests is that the current system is not just broken—it’s actively working against the people it’s supposed to serve. Until we address these fundamental issues, stories like Excellus’s will keep repeating.
In the end, the billion-dollar question isn’t just about where the money is going. It’s about whether we have the collective will to fix a system that’s failing us all.
